CD19 and neoplasm: A study by Hong et al. demonstrated that activated CD30 and CD19 targeting CAR T cells (in a tumor milieu containing antigen positive as well as antigen negative tumor cells) were able to mediate tumor lysis against the antigen negative fraction in an antigen independent, cell–cell contact-mediated manner.